CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled / 20 target
Drug / intervention
Denosumabdrug
Likely dose
Denosumab 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03839459
NCT03839459Phase 2CompletedUpdate Overdue (0.2/mo)Completion was 45mo ago
CompareCT.gov

Denosumab for Smoldering Multiple Myeloma

University of Rochester·interventional·Posted Feb 15, 2019·Updated Jun 15, 2026

In Brief

A Phase 2 clinical trial evaluating Denosumab for Smoldering Multiple Myeloma. Completed, enrolled 20 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoldering Multiple Myeloma
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 15, 2019
Enrollment StartApr 19, 2019
Primary CompletionSep 16, 2022
Study CompletionJan 30, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.4 years ago

Arms & Interventions

Denosumabexperimental

Drug: Denosumab

Interventions

Denosumabdrug

120mg of Denosumab will be administered subcutaneously once every 4 weeks